Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

65.67
-0.8700-1.31%
Post-market: 65.670.00000.00%17:01 EST
Volume:1.40M
Turnover:91.95M
Market Cap:8.03B
PE:-10.39
High:66.95
Open:66.49
Low:65.36
Close:66.54
52wk High:69.33
52wk Low:29.31
Shares:122.26M
Float Shares:119.09M
Volume Ratio:0.89
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3179
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.93%
PB:-15.41
PE(LYR):-12.47

Loading ...

B. Riley Adjusts Price Target on Cytokinetics to $90 From $80, Maintains Buy Rating

MT Newswires Live
·
Nov 10

Cytokinetics Reports Aficamten Outperforms Metoprolol in HCM Exercise Capacity Trial

Reuters
·
Nov 10

Cytokinetics Presents Additional Data From Maple-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

THOMSON REUTERS
·
Nov 10

Cytokinetics (CYTK) Gets a Buy from Evercore ISI

TIPRANKS
·
Nov 06

Strategic Positioning and Launch Readiness Propel Cytokinetics to ‘Buy’ Rating

TIPRANKS
·
Nov 06

Earnings Flash (CYTK) Cytokinetics Posts Q3 Loss $2.55 vs. FactSet Est of $1.57 Loss

MT Newswires Live
·
Nov 06

Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens

Reuters
·
Nov 06

Cytokinetics Q3 EPS $(2.25) Misses $(1.57) Estimate, Sales $1.936M Miss $3.556M Estimate

Benzinga
·
Nov 06

BRIEF-Cytokinetics Q3 Basic EPS USD -2.55

Reuters
·
Nov 06

Cytokinetics Reports Q3 Revenue of $1.9 Million

Reuters
·
Nov 06

Cytokinetics Q3 Net Income USD -306.178 Million

THOMSON REUTERS
·
Nov 06

Cytokinetics Faces Investor Class Action Over Securities Fraud Allegations

Reuters
·
Nov 06

Cytokinetics EVP Research & Development Fady Ibraham Malik Reports Disposal of Common Shares

Reuters
·
Nov 05

Cytokinetics to Participate in November Investor Conferences

GlobeNewswire
·
Nov 05

Cytokinetics (CYTK): Reassessing Valuation After Lawsuit Reveals Regulatory Risks for Key Heart Drug

Simply Wall St.
·
Nov 05

Cytokinetics Unveils New Data on Aficamten and Metoprolol in Hypertrophic Cardiomyopathy Trial

Reuters
·
Oct 31

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

THOMSON REUTERS
·
Oct 31

Cytokinetics CEO Makes Significant Stock Sale!

TIPRANKS
·
Oct 31

Cytokinetics CEO Robert I. Blum Reports Sale of Common Shares

Reuters
·
Oct 31

Cytokinetics Director Makes a Bold Move with Stock Sale

TIPRANKS
·
Oct 28